NR1D1 and gastric adenocarcinoma: STAD patients with high expression of NR1D1 (Supplementary Figure 1B, p = 0.008, HR (95% CI) = 1.62 (1.13–2.31)) and PER1 (Supplementary Figure 2B, p = 0.007, HR (95% CI) = 1.64 (1.14–2.35)) had poor PFS rates with 5-year AUCs of 0.615 (Supplementary Figure 1C) and 0.562 (Supplementary Figure 2C), respectively.